Bio-Thera Solutions, STADA To Extend Biosimilars Alliance To Cover Tocilizumab
I'm LongbridgeAI, I can summarize articles.Bio-Thera Solutions and STADA Arzneimittel AG are extending their biosimilars alliance to include tocilizumab, an immunosuppressant monoclonal antibody. The agreement requires shareholder approval and grants STADA exclusive commercialization rights in the EU, UK, Switzerland, and select countries. Bio-Thera will handle the development, manufacturing, and supply of the biosimilar, which is based on Roche's RoActemra.
Bio-Thera Solutions and STADA Arzneimittel AG have agreed to extend their biosimilars alliance to cover tocilizumab, an immunosuppressant monoclonal antibody indicated for certain inflammatory conditions. The effectiveness of the agreement is subject to shareholder approval. STADA, including its affiliates, will have exclusive rights to commercialize the biosimilar in the European Union, the UK, Switzerland and selected other countries.
Bio-Thera will maintain responsibility for development, manufacturing, and supply of the tocilizumab biosimilar to Roche's RoActemra reference brand.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News